Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2011 Scrip 100: Asian-flavoured pharma deals

This article was originally published in Scrip

Executive Summary

Expanding healthcare coverage in emerging Asia-Pacific (APAC) markets, rapid economic development and burgeoning middle classes are driving growth for APAC-based pharmaceutical companies and attracting foreign companies attempting to offset future losses from the looming 2011 'patent cliff'. Erin Brady, healthcare analyst at Datamonitor, examines how companies are using mergers and acquisitions to strengthen their presence in this booming region.

You may also be interested in...



Positive vote for Lorqess (and Qnexa) is no guarantee of obe$ity $uccess

Arena's Lorqess (lorcaserin) has moved one step closer to approval for the treatment of obesity following a positive review by the FDA advisory committee. The result came as a surprise to some, after the drug was rejected in 2010 due to safety concerns. Despite the good news for Arena Pharmaceuticals, the drug's commercial prospects remain uncertain: the path to launch is unclear, and uptake may be slow.

Price cuts put pressure on South Korean pharma

The South Korean pharmaceutical market was valued at around $11 billion in 2010 with 10% growth forecast through 2014, driven by a rapidly ageing population, increasing prevalence of chronic disease, harmonisation with international standards and strengthening international trade relationships.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel